CLL442 / Novartis - LARVOL DELTA

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis) (clinicaltrials.gov) - P1; N=40; Terminated; Sponsor: Novartis Pharmaceuticals; Completed ➔ Terminated; The study fully enrolled and completed after last patient completed the study

Clinical • Trial termination • Oncology • Squamous Cell Carcinoma